Puretech Health PLC (LON:PRTC) had its Buy rating reiterated by Liberum Capital

Analyst Ratings For Puretech Health PLC (LON:PRTC)

Story continues below

Today, Liberum Capital reiterated its Buy rating on Puretech Health PLC (LON:PRTC).

There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Puretech Health PLC (LON:PRTC) is Buy with a consensus target price of GBX 268.75 per share, a potential .

Some recent analyst ratings include

  • 2/14/2019-Puretech Health PLC (LON:PRTC) had its Buy rating reiterated by Liberum Capital
  • 2/14/2019-Puretech Health PLC (LON:PRTC) had its Buy rating reiterated by Peel Hunt
  • 3/2/2018-Puretech Health PLC (LON:PRTC) had its Buy rating reiterated by N+1 Singer
  • 2/20/2018-Puretech Health PLC (LON:PRTC) had its Buy rating reiterated by Numis Securities with a GBX 259 price target

    About Puretech Health PLC (LON:PRTC)
    PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

    Recent Trading Activity for Puretech Health PLC (LON:PRTC)
    Shares of Puretech Health PLC closed the previous trading session at 176,95 up +5,95 3,48 % with shares trading hands.

    An ad to help with our costs